c-Met/HGFR



c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

c-Met/HGFR Inhibitors & Modulators

2-Phospho-L-ascorbic acid trisodium salt (L-Ascorbic acid 2-phosphate trisodium salt; ...)

Cat. No.: HY-107837

Bioactivity: 2-Phospho-L-ascorbic acid trisodium salt acts as an antioxidant and a stimulator of hepatocyte growth factor **(HGF)** production.

Purity: 99.36%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 1 g



Altiratinib (DCC-2701)

Cat. No.: HY-B0791

Bioactivity: Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with **IC_{50}**s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for **MET**, **TIE2**, **VEGFR2**, **FLT3**, **Trk1**, **Trk2**, and **Trk3** respectively.

Purity: 95.95%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AMG-208

Cat. No.: HY-12035

Bioactivity: AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 9.3 nM. IC50 value: 9.3 nM Target: c-Met in vitro: AMG-208 shows the potent inhibition of kinase c-Met activity with IC50 of 9 nM in a cell-free assay. Besides, AMG-208 treatment also leads to the inhibition of HGF-mediated c-Met...

Purity: 99.34%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AMG-337

Cat. No.: HY-18696

Bioactivity: AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays.

Purity: 99.26%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg



BMS 777607 (BMS 817378)

Cat. No.: HY-12076

Bioactivity: BMS 777607 is a **Met-related** inhibitor for **c-Met**, **Axl**, **Ron** and **Tyro3** with **IC_{50}**s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor...

Purity: 98.32%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



BMS-794833

Cat. No.: HY-10497

Bioactivity: BMS-794833 is a **VEGFR2** and **Met** inhibitor extracted from patent WO2009094417, compound example 1; has **IC_{50}**s of 15 and 1.7 nM, respectively.

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



c-Kit-IN-1

Cat. No.: HY-15240

Bioactivity: c-Kit-IN-1 is a potent inhibitor of **c-Kit** and **c-Met** with **IC_{50}**s of <200 nM.

Purity: 98.46%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



c-Met inhibitor 1

Cat. No.: HY-15735

Bioactivity: c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer.

Purity: 98.72%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



c-Met-IN-2

Cat. No.: HY-101773

Bioactivity: c-Met-IN-2 is a potent, selective and orally available **c-Met** inhibitor, with an **IC_{50}** of 0.6 nM, with antitumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Cabozantinib (XL184; BMS-907351)

Cat. No.: HY-13016

Bioactivity: Cabozantinib is a potent multiple receptor tyrosine kinases inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with **IC_{50}**s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

Purity: 99.92%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Tel: 4008203792 Fax: 021-53700325 Email: sales@MedChemExpress.cn

Capmatinib
(INCB28060; INC-280) Cat. No.: HY-13404

Bioactivity: Capmatinib (INCB28060) is a potent and selective **c-MET** kinase inhibitor. Capmatinib (INCB28060) inhibits c-MET kinase activity with an average **IC_{50}** of 0.13 nM.

Purity: 99.84%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



CEP-40783
(RXDX-106) Cat. No.: HY-100946

Bioactivity: CEP-40783 is a potent, selective and orally available inhibitor of **AXL** and **c-Met** with **IC_{50}** values of 7 nM and 12 nM, respectively.

Purity: 98.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Crizotinib
(PF-02341066) Cat. No.: HY-50878

Bioactivity: Crizotinib is a potent inhibitor of **c-Met** and **ALK** with an **IC_{50}** of 11 nM and 24 nM in cell-based assays, respectively.

Purity: 99.97%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Crizotinib hydrochloride
(PF-02341066 hydrochloride) Cat. No.: HY-50878A

Bioactivity: Crizotinib hydrochloride is a potent inhibitor of **c-Met** and **ALK** with **IC_{50}**s of 11 nM and 24 nM in cell-based assays, respectively.

Purity: 99.86%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Dihexa (PNB-0408; N-hexanoic-Try-Ile-(6)-amino hexanoic amide; Hexanoyl-Tyr-Ile-Ahx-NH2)
Cat. No.: HY-16969

Bioactivity: Dihexa is an orally active, blood-brain barrier-permeable angiotensin IV analog; exhibits high affinity binding hepatocyte growth factor (**HGF**) with a **K_d** of 65 pM.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Ensartinib
(X-396) Cat. No.: HY-103714

Bioactivity: Ensartinib (X-396) is a potent and dual **ALK**/ **MET** inhibitor with **IC_{50}**s of <0.4 nM and 0.74 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Ensartinib hydrochloride
(X-396 hydrochloride) Cat. No.: HY-103714A

Bioactivity: Ensartinib hydrochloride (X-396 hydrochloride) is a potent and dual **ALK**/ **MET** inhibitor with **IC_{50}**s of <0.4 nM and 0.74 nM, respectively.

Purity: 98.51%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg



Foretinib
(XL880; GSK1363089; GSK089; EXEL-2880) Cat. No.: HY-10338

Bioactivity: Foretinib is a multi-target tyrosine kinase inhibitor with **IC_{50}**s of 0.4 nM and 0.9 nM for **Met** and **KDR**.

Purity: 99.81%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Glesatinib hydrochloride
(MGCD265 hydrochloride) Cat. No.: HY-19642A

Bioactivity: Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered. Target: MET, Axl Glesatinib is an orally bioavailable, small-molecule, multitargeted tyrosine kinase inhibitor with potential antineoplastic activity. MGCD265...

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg



Golvatinib
(E-7050) Cat. No.: HY-13068

Bioactivity: Golvatinib (E-7050) is a potent dual inhibitor of both **c-Met** and **VEGFR2** kinases with **IC_{50}**s of 14 and 16 nM, respectively.

Purity: 99.29%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-38877605

Cat. No.: HY-50683

Bioactivity: JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. IC50 value: 4 nM [1] Target: c-Met in vitro: JNJ-38877605 shows more than 600-fold selectivity for c-Met compared with more than 200 other...
Purity: 99.96%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



JNJ-38877618

Cat. No.: HY-111050

Bioactivity: JNJ-38877618 is a potent, highly selective, orally bioavailable **Met** kinase inhibitor with **IC_{50}**s of 2 and 3 nM for wild type and mutant Met, respectively.
Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg

Merestinib

(LY2801653)

Cat. No.: HY-15514

Bioactivity: Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of **MET** tyrosine kinase with a dissociation constant (**K_i**) of 2 nM.
Purity: 99.71%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Merestinib dihydrochloride

(LY2801653 (dihydrochloride))

Cat. No.: HY-15514A

Bioactivity: Merestinib dihydrochloride (LY2801653 dihydrochloride) is a type-II ATP competitive, slow-off inhibitor of **MET** tyrosine kinase with a dissociation constant (**K_i**) of 2 nM.
Purity: 98.88%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



MGCD-265 analog

Cat. No.: HY-10991

Bioactivity: MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively. IC50 value:10 nM (VEGFR2), 29 nM(c-Met) [1] Target:VEGFR, c-Met in vivo:...
Purity: 96.53%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg



MK-2461

Cat. No.: HY-50703

Bioactivity: MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a mean IC50 of 2.5 nM.
Purity: 99.88%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg



MK-8033

Cat. No.: HY-13299

Bioactivity: MK8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
Purity: 98.0%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg



MK-8033 hydrochloride

Cat. No.: HY-13299A

Bioactivity: MK8033 Hcl is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
Purity: >98%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg



Ningetinib

Cat. No.: HY-107145A

Bioactivity: Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with **IC_{50}**s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.
Purity: 98.75%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Ningetinib Tosylate

Cat. No.: HY-107145

Bioactivity: Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (**TKI**) with **IC_{50}**s of 6.7, 1.9 and <1.0 nM for **c-Met**, **VEGFR2** and **Axl**, respectively.
Purity: 99.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



NPS-1034

Cat. No.: HY-100509

Bioactivity: NPS-1034 is a dual inhibitor of **AXL** and **MET** with **IC_{50}**s of 10.3 and 48 nM, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



NVP-BVU972

Cat. No.: HY-15456

Bioactivity: NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM). Antitumor agents.

Purity: 97.35%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



PF-04217903

Cat. No.: HY-12017

Bioactivity: PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant). IC50 value: 4.8 nM [1] Target: in vitro: Being more selective than staurosporine or PF-02341066, PF-04217903 displays >1000-fold selectivity for c-Met over...

Purity: 99.59%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PF-04217903 methanesulfonate

Cat. No.: HY-12017A

Bioactivity: PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).

Purity: 99.87%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PHA-665752

Cat. No.: HY-11107

Bioactivity: PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM, >50-fold selectivity for c-Met than RTKs or STKs. IC50 value: 9 nM Target: c-Met in vitro: PHA-665752 significantly inhibits c-Met kinase activity with Ki of 4 nM, and exhibits >50-fold selectivity for c-Met...

Purity: 96.50%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

S49076

Cat. No.: HY-12965

Bioactivity: S49076 is a novel, potent inhibitor of **MET**, **AXL/MER**, and **FGFR1/2/3** with **IC_{50}** values below 20 nM.

Purity: 98.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Savolitinib

(Volitinib; HMPL-504; AZD-6094)

Cat. No.: HY-15959

Bioactivity: Savolitinib (AZD6094) ia highly potent and selective **c-Met** inhibitor with an **IC_{50}** of 5 nM.

Purity: 98.45%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



SCR-1481B1

(c-Met inhibitor 2)

Cat. No.: HY-18711A

Bioactivity: SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



SGX-523

Cat. No.: HY-12019

Bioactivity: SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. IC50 value: 4 nM [1] Target: Met in vitro: SGX-523 belongs to the class of c-Met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors. SGX-523 stabilizes MET in a unique inactive...

Purity: 98.0%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SU11274

(PKI-SU11274)

Cat. No.: HY-12014

Bioactivity: SU11274 is a selective **Met** inhibitor with **IC_{50}** of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.

Purity: 98.09%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



TAS-115

Cat. No.: HY-12423

Bioactivity: TAS-115 is a potent **VEGFR** and hepatocyte growth factor receptor (**c-Met/HGFR**)-targeted kinase inhibitor with $\mathbf{IC_{50}}$s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



TAS-115 mesylate

(TAS-115 methanesulfonate)

Cat. No.: HY-12423A

Bioactivity: TAS-115 mesylate is a potent vascular endothelial growth factor (**VEGFR**) and hepatocyte growth factor receptor (**c-Met/HGFR**)-targeted kinase inhibitor, with $\mathbf{IC_{50}}$s of 30 and 32 nM for rVEGFR2 and rMET, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Tepotinib

(EMD-1214063)

Cat. No.: HY-14721

Bioactivity: EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. IC50 Value: 4 nM [1] Target: c-Met in vitro: EMD 1214063 inhibits HGF-induced c-Met phosphorylation in A549 cells with IC50 of 6 nM. Treatment...

Purity: 99.80%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Tivantinib

(ARQ 197)

Cat. No.: HY-50686

Bioactivity: Tivantinib is a novel and highly selective **c-Met** tyrosine kinase inhibitor with $\mathbf{K_i}$ of 355 nM.

Purity: 99.39%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



Tyrosine kinase inhibitor

Cat. No.: HY-10421

Bioactivity: A Tyrosine kinase inhibitor.

Purity: 99.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg



X-376

Cat. No.: HY-16590

Bioactivity: X-376 is a potent and dual **ALK**/ **MET** inhibitor with $\mathbf{IC_{50}}$s of 0.61 nM and 0.69 nM, respectively.

Purity: 98.02%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Tel: 4008203792 Fax: 021-53700325 Email: sales@MedChemExpress.cn